Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 339

1.

A phase II study of ruxolitinib in combination with azacytidine in patients with myelofibrosis.

Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver N.

Blood. 2018 Sep 5. pii: blood-2018-04-846626. doi: 10.1182/blood-2018-04-846626. [Epub ahead of print]

PMID:
30185431
2.

De novo lipogenesis represents a therapeutic target in mutant Kras non-small cell lung cancer.

Singh A, Ruiz C, Bhalla K, Haley JA, Li QK, Acquaah-Mensah G, Montal E, Sudini KR, Skoulidis F, Wistuba II, Papadimitrakopoulou V, Heymach JV, Boros LG, Gabrielson E, Carretero J, Wong KK, Haley JD, Biswal S, Girnun GD.

FASEB J. 2018 Jun 15:fj201800204. doi: 10.1096/fj.201800204. [Epub ahead of print]

PMID:
29906244
3.

Schistosomiasis Induces Persistent DNA Methylation and Tuberculosis-Specific Immune Changes.

DiNardo AR, Nishiguchi T, Mace EM, Rajapakshe K, Mtetwa G, Kay A, Maphalala G, Secor WE, Mejia R, Orange JS, Coarfa C, Bhalla KN, Graviss EA, Mandalakas AM, Makedonas G.

J Immunol. 2018 Jul 1;201(1):124-133. doi: 10.4049/jimmunol.1800101. Epub 2018 May 11.

PMID:
29752313
4.

MYC protein expression is an important prognostic factor in acute myeloid leukemia.

Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-González GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE.

Leuk Lymphoma. 2018 May 9:1-12. doi: 10.1080/10428194.2018.1464158. [Epub ahead of print]

PMID:
29741984
5.

Author Correction: Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL.

Bhalla K, Jaber S, Nahid M N, Underwood K, Beheshti A, Landon A, Bhandary B, Bastian P, Evens AM, Haley J, Polster B, Gartenhaus RB.

Sci Rep. 2018 May 3;8(1):7221. doi: 10.1038/s41598-018-25251-9.

6.

Estimating city-level travel patterns using street imagery: A case study of using Google Street View in Britain.

Goel R, Garcia LMT, Goodman A, Johnson R, Aldred R, Murugesan M, Brage S, Bhalla K, Woodcock J.

PLoS One. 2018 May 2;13(5):e0196521. doi: 10.1371/journal.pone.0196521. eCollection 2018.

7.

Fatty Acid Synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL.

Kapadia B, Nanaji NM, Bhalla K, Bhandary B, Lapidus R, Beheshti A, Evens AM, Gartenhaus RB.

Nat Commun. 2018 Feb 26;9(1):829. doi: 10.1038/s41467-018-03028-y.

8.

Unilateral Transient Watershed Cerebral Infarct in a 6-Year-Old Girl with Frequently Relapsing Nephrotic Syndrome.

Bhalla K, Garg D, Rajan M, Kaushik JS, Gathwala G.

J Nat Sci Biol Med. 2018 Jan-Jun;9(1):90-92. doi: 10.4103/jnsbm.JNSBM_133_17.

9.

Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL.

Bhalla K, Jaber S, Nahid M N, Underwood K, Beheshti A, Landon A, Bhandary B, Bastian P, Evens AM, Haley J, Polster B, Gartenhaus RB.

Sci Rep. 2018 Jan 15;8(1):744. doi: 10.1038/s41598-018-19182-8. Erratum in: Sci Rep. 2018 May 3;8(1):7221.

10.

Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis.

Boddu P, Kantarjian HM, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E, Borthakur G, Konopleva M, Bhalla KN, Daver N, DiNardo CD, Benton CB, Takahashi K, Estrov Z, Pierce SR, Andreeff M, Cortes JE, Kadia TM.

Blood Adv. 2017 Jul 19;1(17):1312-1323. doi: 10.1182/bloodadvances.2017008227. eCollection 2017 Jul 25.

11.

Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.

DiNardo CD, Rausch CR, Benton C, Kadia T, Jain N, Pemmaraju N, Daver N, Covert W, Marx KR, Mace M, Jabbour E, Cortes J, Garcia-Manero G, Ravandi F, Bhalla KN, Kantarjian H, Konopleva M.

Am J Hematol. 2018 Mar;93(3):401-407. doi: 10.1002/ajh.25000. Epub 2017 Dec 23.

PMID:
29218851
12.

Targeting cistrome and dysregulated transcriptome of post-MPN sAML.

Verstovsek S, Fiskus W, Manshouri T, Bhalla KN.

Oncotarget. 2017 Oct 11;8(55):93301-93302. doi: 10.18632/oncotarget.21752. eCollection 2017 Nov 7. No abstract available.

13.

Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia.

Khan M, Cortes J, Kadia T, Naqvi K, Brandt M, Pierce S, Patel KP, Borthakur G, Ravandi F, Konopleva M, Kornblau S, Kantarjian H, Bhalla K, DiNardo CD.

Int J Mol Sci. 2017 Jul 26;18(8). pii: E1618. doi: 10.3390/ijms18081618.

14.

Targeting Histone Acetylation: Readers and Writers in Leukemia and Cancer.

Benton CB, Fiskus W, Bhalla KN.

Cancer J. 2017 Sep/Oct;23(5):286-291. doi: 10.1097/PPO.0000000000000284. Review.

PMID:
28926429
15.

BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells.

Sun B, Fiskus W, Qian Y, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Saenz DT, Mill CP, Nowak AJ, Jain N, Zhang L, Wang M, Khoury JD, Coarfa C, Crews CM, Bhalla KN.

Leukemia. 2018 Feb;32(2):343-352. doi: 10.1038/leu.2017.207. Epub 2017 Jun 30.

PMID:
28663582
16.

A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104).

Goldstein LJ, Zhao F, Wang M, Swaby RF, Sparano JA, Meropol NJ, Bhalla KN, Pellegrino CM, Katherine Alpaugh R, Falkson CI, Klein P, Sledge GW.

Breast Cancer Res Treat. 2017 Sep;165(2):375-382. doi: 10.1007/s10549-017-4310-9. Epub 2017 Jun 16.

17.

HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.

Tharkar-Promod S, Johnson DP, Bennett SE, Dennis EM, Banowsky BG, Jones SS, Shearstone JR, Quayle SN, Min C, Jarpe M, Mosbruger T, Pomicter AD, Miles RR, Chen WY, Bhalla KN, Zweidler-McKay PA, Shrieve DC, Deininger MW, Chandrasekharan MB, Bhaskara S.

Leukemia. 2018 Jan;32(1):49-60. doi: 10.1038/leu.2017.174. Epub 2017 Jun 5.

18.

Impact of improving vehicle front design on the burden of pedestrian injuries in Germany, the United States, and India.

Moran D, Bose D, Bhalla K.

Traffic Inj Prev. 2017 Nov 17;18(8):832-838. doi: 10.1080/15389588.2017.1324200. Epub 2017 May 1.

PMID:
28459283
19.

Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.

Boddu PC, Kantarjian HM, Ravandi F, Garcia-Manero G, Verstovsek S, Jabbour EJ, Takahashi K, Bhalla K, Konopleva M, DiNardo CD, Ohanian M, Pemmaraju N, Jain N, Pierce S, Wierda WG, Cortes JE, Kadia TM.

Cancer. 2017 Aug 15;123(16):3050-3060. doi: 10.1002/cncr.30704. Epub 2017 Apr 7.

20.

Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.

Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SGT, Liu K, Iyer SP, Bearss D, Bhalla KN.

Leukemia. 2017 Jul;31(7):1658. doi: 10.1038/leu.2017.77. Epub 2017 Mar 21.

PMID:
28322226
21.

Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.

Saenz DT, Fiskus W, Qian Y, Manshouri T, Rajapakshe K, Raina K, Coleman KG, Crew AP, Shen A, Mill CP, Sun B, Qiu P, Kadia TM, Pemmaraju N, DiNardo C, Kim MS, Nowak AJ, Coarfa C, Crews CM, Verstovsek S, Bhalla KN.

Leukemia. 2017 Sep;31(9):1951-1961. doi: 10.1038/leu.2016.393. Epub 2017 Feb 2.

22.

Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.

Cortes J, Talpaz M, Smith HP, Snyder DS, Khoury J, Bhalla KN, Pinilla-Ibarz J, Larson R, Mitchell D, Wise SC, Rutkoski TJ, Smith BD, Flynn DL, Kantarjian HM, Rosen O, Van Etten RA.

Haematologica. 2017 Mar;102(3):519-528. doi: 10.3324/haematol.2016.152710. Epub 2016 Dec 7.

23.

Giant Primary Epithelial Splenic Cyst in an Adolescent Girl.

Kajal P, Rattan KN, Bhutani N, Bhalla K.

APSP J Case Rep. 2016 Nov 1;7(5):42. eCollection 2016 Nov-Dec. No abstract available.

24.

Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85α, androgen receptor, and Src.

Sun M, Yang L, Feldman RI, Sun XM, Bhalla KN, Jove R, Nicosia SV, Cheng JQ.

J Biol Chem. 2016 Oct 21;291(43):22841. No abstract available.

25.

BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.

Saenz DT, Fiskus W, Manshouri T, Rajapakshe K, Krieger S, Sun B, Mill CP, DiNardo C, Pemmaraju N, Kadia T, Parmar S, Sharma S, Coarfa C, Qiu P, Verstovsek S, Bhalla KN.

Leukemia. 2017 Mar;31(3):678-687. doi: 10.1038/leu.2016.260. Epub 2016 Sep 28.

26.

Estimating the burden of injury in urban and rural Sudan in 2008.

Abdalla S, Ahmed S, Swareldahab Z, Bhalla K; Sudan Burden of Injury Team.

Inj Prev. 2017 Jun;23(3):171-178. doi: 10.1136/injuryprev-2016-042067. Epub 2016 Oct 11.

PMID:
27729441
27.

Asplenia Syndrome in a Neonate: A Case Report.

Bhalla K, Singh J, Yadav J, Mehra S.

J Clin Diagn Res. 2016 Jun;10(6):SD05-6. doi: 10.7860/JCDR/2016/18535.8028. Epub 2016 Jun 1.

28.

SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing Agents.

Fiskus W, Coothankandaswamy V, Chen J, Ma H, Ha K, Saenz DT, Krieger SS, Mill CP, Sun B, Huang P, Mumm JS, Melnick AM, Bhalla KN.

Cancer Res. 2016 Sep 15;76(18):5467-78. doi: 10.1158/0008-5472.CAN-16-0126. Epub 2016 Aug 8.

29.

Official government statistics of road traffic deaths in India under-represent pedestrians and motorised two wheeler riders.

Bhalla K, Khurana N, Bose D, Navaratne KV, Tiwari G, Mohan D.

Inj Prev. 2017 Feb;23(1):1-7. doi: 10.1136/injuryprev-2016-042053. Epub 2016 Jul 25.

PMID:
27457243
30.

Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC).

DiNardo CD, Bannon SA, Routbort M, Franklin A, Mork M, Armanios M, Mace EM, Orange JS, Jeff-Eke M, Churpek JE, Takahashi K, Jorgensen JL, Garcia-Manero G, Kornblau S, Bertuch A, Cheung H, Bhalla K, Futreal A, Godley LA, Patel KP.

Clin Lymphoma Myeloma Leuk. 2016 Jul;16(7):417-428.e2. doi: 10.1016/j.clml.2016.04.001. Epub 2016 Apr 27.

31.

NEDD8 and HDACs: promising cotargets in AML.

Bhalla KN, Fiskus W.

Blood. 2016 May 5;127(18):2168-70. doi: 10.1182/blood-2016-02-699058. No abstract available.

32.

Neonatal Adrenal Hemorrhage presenting as Prolonged Hyperbilirubinemia.

Singh J, Dalal P, Bhalla K, Rattan KN.

J Neonatal Surg. 2016 Apr 10;5(2):22. eCollection 2016 Apr-Jun. No abstract available.

33.

Burden Calculator: a simple and open analytical tool for estimating the population burden of injuries.

Bhalla K, Harrison JE.

Inj Prev. 2016 Apr;22 Suppl 1:i23-6. doi: 10.1136/injuryprev-2015-041816. Epub 2015 Dec 9.

PMID:
26658340
34.

PEPCK Coordinates the Regulation of Central Carbon Metabolism to Promote Cancer Cell Growth.

Montal ED, Dewi R, Bhalla K, Ou L, Hwang BJ, Ropell AE, Gordon C, Liu WJ, DeBerardinis RJ, Sudderth J, Twaddel W, Boros LG, Shroyer KR, Duraisamy S, Drapkin R, Powers RS, Rohde JM, Boxer MB, Wong KK, Girnun GD.

Mol Cell. 2015 Nov 19;60(4):571-83. doi: 10.1016/j.molcel.2015.09.025. Epub 2015 Oct 17.

35.

Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.

Sun B, Shah B, Fiskus W, Qi J, Rajapakshe K, Coarfa C, Li L, Devaraj SG, Sharma S, Zhang L, Wang ML, Saenz DT, Krieger S, Bradner JE, Bhalla KN.

Blood. 2015 Sep 24;126(13):1565-74. doi: 10.1182/blood-2015-04-639542. Epub 2015 Aug 7. Erratum in: Blood. 2016 Sep 29;128(13):1778.

36.

Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors.

Patnaik A, Tolcher A, Beeram M, Nemunaitis J, Weiss GJ, Bhalla K, Agrawal M, Nichols G, Middleton S, Beryozkina A, Sarapa N, Peck R, Zhi J.

Cancer Chemother Pharmacol. 2015 Sep;76(3):587-95. doi: 10.1007/s00280-015-2830-8. Epub 2015 Jul 26.

PMID:
26210682
37.

Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime β-Catenin Pathway Inhibitors.

Soldi R, Horrigan SK, Cholody MW, Padia J, Sorna V, Bearss J, Gilcrease G, Bhalla K, Verma A, Vankayalapati H, Sharma S.

J Med Chem. 2015 Aug 13;58(15):5854-62. doi: 10.1021/acs.jmedchem.5b00460. Epub 2015 Jul 31.

PMID:
26182238
38.

HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist.

Devaraj SG, Fiskus W, Shah B, Qi J, Sun B, Iyer SP, Sharma S, Bradner JE, Bhalla KN.

Leukemia. 2016 Feb;30(2):504-8. doi: 10.1038/leu.2015.142. Epub 2015 Jun 15. No abstract available.

39.

Computed Tomography in Diagnosis of Admantinoma.

Misra A, Misra D, Rai S, Panjwani S, Ranjan V, Prabhat M, Bhalla K, Bhatnagar P.

N Am J Med Sci. 2015 May;7(5):229-32. doi: 10.4103/1947-2714.157493.

40.

Long-term outcomes of individuals injured in motor vehicle crashes: A population-based study.

Alghnam S, Wegener ST, Bhalla K, Colantuoni E, Castillo R.

Injury. 2015 Aug;46(8):1503-8. doi: 10.1016/j.injury.2015.06.004. Epub 2015 Jun 11.

PMID:
26100209
41.

Benign and Infected Sacrococcygeal Teratoma in a 13-year-old Girl.

Rattan KN, Bhalla K, Singh J, Rattan H.

APSP J Case Rep. 2015 May 1;6(2):20. eCollection 2015 May-Aug. No abstract available.

42.

Automated speed enforcement systems to reduce traffic-related injuries: closing the policy implementation gap.

Morain SR, Gielen AC, Bhalla K.

Inj Prev. 2016 Feb;22(1):79-83. doi: 10.1136/injuryprev-2014-041507. Epub 2015 May 25. No abstract available.

PMID:
26007230
43.

Evidence to inform intersectoral policies: a comparison of health and transport sector evidence in support of road traffic injury prevention.

Bao J, Bhalla K, Bennett S.

Health Res Policy Syst. 2015 Mar 25;13:19. doi: 10.1186/s12961-015-0008-9.

44.

GBD-2010 overestimates deaths from road injuries in OECD countries: new methods perform poorly.

Bhalla K, Harrison JE.

Int J Epidemiol. 2015 Oct;44(5):1648-56. doi: 10.1093/ije/dyv019. Epub 2015 Mar 29.

PMID:
25817298
45.

Dentinogenic ghost cell tumor - a neoplastic variety of calcifying odontogenic cyst: case presentation and review.

Rai S, Prabhat M, Goel S, Bhalla K, Panjwani S, Misra D, Agarwal A, Bhatnagar G.

N Am J Med Sci. 2015 Jan;7(1):19-23. doi: 10.4103/1947-2714.150084.

46.

Host ICAMs play a role in cell invasion by Mycobacterium tuberculosis and Plasmodium falciparum.

Bhalla K, Chugh M, Mehrotra S, Rathore S, Tousif S, Prakash Dwivedi V, Prakash P, Kumar Samuchiwal S, Kumar S, Kumar Singh D, Ghanwat S, Kumar D, Das G, Mohmmed A, Malhotra P, Ranganathan A.

Nat Commun. 2015 Jan 14;6:6049. doi: 10.1038/ncomms7049.

PMID:
25586702
47.

Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells.

Fiskus W, Sharma S, Saha S, Shah B, Devaraj SG, Sun B, Horrigan S, Leveque C, Zu Y, Iyer S, Bhalla KN.

Leukemia. 2015 Jun;29(6):1267-78. doi: 10.1038/leu.2014.340. Epub 2014 Dec 8.

48.

A novel peptide interferes with Mycobacterium tuberculosis virulence and survival.

Samuchiwal SK, Tousif S, Singh DK, Kumar A, Ghosh A, Bhalla K, Prakash P, Kumar S, Trivedi AC, Bhattacharyya M, Das G, Ranganathan A.

FEBS Open Bio. 2014 Aug 7;4:735-40. doi: 10.1016/j.fob.2014.08.001. eCollection 2014.

49.

BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD.

Fiskus W, Sharma S, Qi J, Shah B, Devaraj SG, Leveque C, Portier BP, Iyer S, Bradner JE, Bhalla KN.

Mol Cancer Ther. 2014 Oct;13(10):2315-27. doi: 10.1158/1535-7163.MCT-14-0258. Epub 2014 Jul 22.

50.

Rapid assessment of road safety policy change: relaxation of the national speed enforcement law in Russia leads to large increases in the prevalence of speeding.

Bhalla K, Paichadze N, Gupta S, Kliavin V, Gritsenko E, Bishai D, Hyder AA.

Inj Prev. 2015 Feb;21(1):53-6. doi: 10.1136/injuryprev-2014-041189. Epub 2014 Jul 22.

PMID:
25052496

Supplemental Content

Loading ...
Support Center